Skip to main content

Table 9 TEAEs by age group in the crossover phase while receiving LDX with an incidence of ≥10% in the dose-optimization and/or crossover phase

From: Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day

AE-Preferred Term

Crossover Phase

 

6 to 9 year olds

10 to 12 year olds

 

(n = 42)

(n = 73)

 

n (%)

n (%)

Any AE

16 (38.1)

22 (30.1)

Abdominal pain upper

1 (2.4)

1 (1.4)

Affect lability

0 (0.0)

0 (0.0)

Anorexia

0 (0.0)

0 (0.0)

Decreased appetite

2 (4.8)

5 (6.8)

Headache

2 (4.8)

4 (5.5)

Insomnia

3 (7.1)

2 (2.7)

Irritability

1 (2.4)

0 (0.0)